Abstract
Ripretinib (QINLOCK (TM)) is a novel type II tyrosine switch control inhibitor being developed by Deciphera Pharmaceuticals for the treatment of KIT p......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
